Evidence map›Paper›PMID 29294201›Full record

ArticlePharmaceutical research2018

Leukemia Inhibitory Factor-Loaded Nanoparticles with Enhanced Cytokine Metabolic Stability and Anti-Inflammatory Activity.

Stephanie M Davis, Derek Reichel, Younsoo Bae, Keith R Pennypacker

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Macrophage Phenotyping in Atherosclerosis by Proteomics.International journal of molecular sciences · 2023
    Review
  6. Leukaemia inhibitory factor in gastric cancer: friend or foe?Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Stephanie M DavisDepartment of Neurology, College of Medicine, University of Kentucky, 741 South Limestone, Lexington, Kentucky, 40536, USA.
Derek ReichelDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone, Lexington, Kentucky, 40536, USA.
Younsoo BaeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone, Lexington, Kentucky, 40536, USA.
Keith R PennypackerDepartment of Neurology, College of Medicine, University of Kentucky, 741 South Limestone, Lexington, Kentucky, 40536, USA. keith.pennypacker@uky.edu.ORCID http://orcid.org/0000-0002-4618-0903
University of Kentucky · US

Funding

Anti-Oxidant Promoting Cytokine LIF Enhances Neural Cell Survival During IschemiaR01NS091146 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI PENNYPACKER, KEITH R · 2016 to 2019
$1.4M
NINDS NIH HHS 5R01NS091146-03NINDS NIH HHS R01 NS091146
6 · The paper itself

Abstract

purposeTo synthesize and assess the in vitro biological activity of nanoparticles containing leukemia inhibitory factor (LIF). These NanoLIF particles are designed to prolong the neuroprotective and anti-inflammatory actions of LIF in future preclinical studies of ischemic stroke.

methodsLIF was packaged in nanoparticles made of poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) polymer to form LIF-loaded nanoparticles (NanoLIF). The surface of NanoLIF was also modified with the CD11b antibody (CD11b-NanoLIF) targeting activated peripheral macrophages to increase cytokine delivery to inflammatory macrophages. ELISA was used to quantify bioactive cytokine inside and releasing from NanoLIF. NanoLIF biological activity was measured using the M1 murine leukemia cell proliferation assay.

resultsNanoLIF and CD11b-NanoLIF had diameters of approximately 30 nm, neutral surface charge, and physicochemical stability retaining biological activity of the cytokine during incubation at 25°C for 12 h. NanoLIF particles released LIF relatively fast from 0 to 6 h after incubation at 37°C followed by slow release from 24 to 72 h according to a two-phase exponential decay model. NanoLIF and CD11b-NanoLIF significantly decreased M1 cell proliferation over 72 h compared to free LIF.

conclusionsNanoLIF and CD11b-NanoLIF preserved the metabolic stability and biological activity of LIF in vitro. These results are promising to improve the therapeutic potential of LIF in treating neurodegenerative and inflammatory diseases.

Indexed as

AnimalsAnti-Inflammatory AgentsBrain IschemiaCD11b AntigenCell Line, TumorCytokinesDrug CarriersDrug LiberationDrug StabilityHumansLeukemia Inhibitory FactorMacrophagesMiceNanoparticlesNeurodegenerative DiseasesParticle SizeAnti-Inflammatory AgentsCD11b AntigenCytokinesDrug CarriersLeukemia Inhibitory Factormonomethoxypolyethyleneglycol-polylactide block copolymerPolyethylene Glycolscytokine deliveryinflammationmacrophagesneurodegenerationstroke

Identifiers

PMID29294201
PMCPMC6265655
OpenAlexW2781934577

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.